about David M. Weiner, M.D.:
Dave Weiner is Chief Medical Officer of Lumos Pharma. Dr. Weiner has over 20 years of experience in the discovery and clinical development of novel therapeutics for neurological disease. He started his career at ACADIA Pharmaceuticals, where, over a ten-year period, he held a series of discovery research and clinical development roles working on multiple CNS therapeutics, most notably Pimavanserin. He subsequently joined EMD Serono, in a late clinical development role, and ultimately heading early clinical development activities in neurology globally. Dave has extensive experience in rare disease drug development, serving as CMO and Interim CEO for Proteostasis Therapeutics Inc., and most recently as CMO at aTYR Pharma, Inc.
Dr. Weiner received his M.D. from the School of Medicine and Biomedical Sciences, SUNY at Buffalo, and was a Howard Hughes Medical Institute Research Scholar at the National Institute of Health in Bethesda. He trained in clinical neurology at New York Hospital, Memorial Sloan Kettering, Cornell Medical Center, and did a post-doctoral fellowship in Neuropharmacology at the University of Vermont. Dr. Weiner’s clinical experiences have included patient care and clinical teaching responsibilities at both the University of Vermont, and the University of California, San Diego.
Dr. Weiner has authored over 30 scientific publications, multiple patents, and serves on a number of clinical and scientific advisory boards, including the scientific advisory board of the Michael J. Fox Foundation for Parkinson Research.